Special Issue

Genomic Instability in Multiple Myeloma and Solid Malignancies: Role of DNA Repair from Prognostic Marker to Therapeutic Target

Message from the Guest Editors

Genomic instability is a common feature of human cancer. Although the molecular bases of genomic instability are largely unknown, growing evidence suggests that impairment of DNA repair machinery plays a crucial role. Multiple Myeloma (MM) is characterized by deep genomic instability that leads to abnormal proliferation of malignant plasma cells, which harbor several karyotype aberrations similar to solid tumors. Indeed, cytogenetic abnormalities are critical prognostic factors, and, at the same time, they represent a potential the epiphenomenon of still unknown therapeutic targets, to be exploited for synthetic lethality. We are pleased to invite manuscripts aimed to elucidate the role of genomic instability as oncogenic driver and therapeutic target in MM and other cancer cells. This Special Issue aims to elucidate strategies to exploit DNA repair deregulation as specific cancer Achilles' heel. Original research articles and reviews are welcome. We are specifically interested in manuscripts investigating the mechanisms underpinning the link among DNA damage induced by inactivation of DNA repair and the immune recognition/destruction of cancer cells.

Guest Editors

Dr. Daniele Caracciolo

Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy

Dr. Masood A. Shammas

Department of Medical Oncology, Harvard (Dana Farber) Cancer Institute, Boston, MA, USA

Deadline for manuscript submissions

closed (30 June 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/133755

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)